FDA accepts for review Merck’s Biologics License Application for V503, investigational 9-valent human papillomavirus vaccine

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration.